Biological therapy for inflammatory bowel disease in children

So Young Na, Jung Ok Shim

    Research output: Contribution to journalReview articlepeer-review

    2 Citations (Scopus)


    The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.

    Original languageEnglish
    Pages (from-to)13-18
    Number of pages6
    JournalPediatric Gastroenterology, Hepatology and Nutrition
    Issue number1
    Publication statusPublished - 2012


    • Children
    • Inflammatory bowel disease
    • Infliximab

    ASJC Scopus subject areas

    • Pediatrics, Perinatology, and Child Health
    • Hepatology
    • Gastroenterology


    Dive into the research topics of 'Biological therapy for inflammatory bowel disease in children'. Together they form a unique fingerprint.

    Cite this